New cocktail aims to shrink Hard-to-Treat stomach tumors
Disease control
Ongoing
This phase 2 trial is testing a combination of three drugs—anlotinib, TQB2450, and the SOX chemotherapy regimen—as a first treatment for advanced stomach or gastroesophageal junction cancer that has low PD-L1 expression. The study involves 37 participants and aims to see how well…
Phase: PHASE2 • Sponsor: Yongxu Jia • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC